Lucas Franki - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Lucas Franki's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Lucas Franki

Lucas Franki

Verified

Associate Editor, Frontline Medical News

Frederick

Final Covers

interest, personal human, travel adventure, historyrussia, quirky ukraine

Doesn’t Cover

I'm not the guy to be measuring trunk size or gas mileage

Journalist Type

-

Seniority Positions

Medium Formats

-

Content

Total articles 495

  • Class of 2015: New drugs projected to earn billions and billions

    By Lucas Franki Verified| MDedge Hematology and Oncology Verified Of all drugs to be released in 2015, the melanoma drug Opdivo (nivolumab) is expected to have the brightest future, according to a report from Thomson Reuters. With sales forecast to reach nearly $5.7 billion by 2019, Opdivo is at the head of a large 2015 “blockbuster” drug class.

    By Lucas Franki Verified · MDedge Hematology and Oncology

    Jan. 16, 2025

  • Ação estimulante do café pode ser efeito placebo? E dentaduras causam pneumonia?

    By Lucas Franki Verified, Richard Franki, Teraya Smith| Medscape PT Verified close Tem certeza que quer sair? Sair Cancelar A melhor parte do despertar é o placebo na sua xícara O café move o mundo. É impossível imaginar qualquer ambiente de trabalho sem um grupo de pessoas desesperadas amontoadas em torno da cafeteira do escritório na manhã de segunda-feira para tomar a sua bebida do dia até serem tiradas do estupor de semi-zumbis.

    By Lucas Franki Verified, Richard Franki, Teraya Smith · Medscape PT

    Aug. 02, 2023

  • Class of 2015: New drugs projected to earn billions and billions

    By Lucas Franki Verified| MDedge Hematology and Oncology Verified Of all drugs to be released in 2015, the melanoma drug Opdivo (nivolumab) is expected to have the brightest future, according to a report from Thomson Reuters. With sales forecast to reach nearly $5.7 billion by 2019, Opdivo is at the head of a large 2015 “blockbuster” drug class.

    By Lucas Franki Verified · MDedge Hematology and Oncology

    Jan. 16, 2025

As seen in

Company Info

Frontline Medical News

The Woodlands, Texas, United States

+1 281-419-5725